** Shares of healthcare company Organon OGN.N rise 11.2% to $16.34
** The developer of drugs for women's health and biosimilars posts Q4 adjusted profit of 90 cents per share vs analysts' average estimate of 87 cents per share - data compiled by LSEG
** Q4 revenue at $1.59 billion, in line with the estimate
** "We expect a slightly positive stock reaction on Q4 EPS beat and better EBITDA guidance, as the revenue guidance was materially impacted by FX," says brokerage BNP Paribas Exane
** Company forecasts 2025 revenue in the range of $6.13 billion to $6.33 billion, below analysts' estimate of $6.47 billion
** OGN shares down ~3% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.